Wolfe Research Initiates Coverage On Taysha Gene Therapies with Outperform Rating
Taysha Gene Therapies Inc TSHA
$4.99
▲ +0.00%
(+$0.00)
⬆️ Above Yest. High
🔥 High Short Interest
Open
$4.97
Prev Close
$4.99
Day Range
$4.80 – $5.03
52W Range
$3.06 – $7.30
Market Cap
$1.63B
Beta
1.39
EPS (TTM)
$-0.41
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-09-24 |
| Shares Out. | 319,780,000 |
| Website | tayshagtx.com/ ↗ |
| Phone | 12146120000 |
| Employees | 99 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$46.6M |
| Free Cash Flow | -$132.6M |
| Total Assets | $470.4M |
| Total Liabilities | $83.2M |
| Equity | $387.3M |
About Taysha Gene Therapies Inc
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Taysha Gene Therapies Inc is a publicly traded company under the ticker symbol TSHA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-09-01)